Shanghai Pharma Holding
Dawei Jiang
Sr. BD ManagerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd
Kelun-Biotech Biopharmaceutical is a subsidiary of Kelun Pharmaceutical Group established in 2016
Looking for antibody and samall molecular out-license and in-license
Chunlin Li
BD btlichl@kelun.comSimcere Pharmaceutical Group
We are rapidly transitioning to an innovation and R&D driven Pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today' s patients with medicines of the future“ We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” 1 and “Top 100 Pharmaceutical Manufacturing Enterprises of China”
Wayne Yin
BD DirectorWanbang Biopharmaceuticals (Group) Co., Ltd
Dr Di Simon
高级BD经理WPD Pharmaceuticals
WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust drug development pipeline with a focus on melanoma, brain cancer, leukemia, and pancreatic cancer. Notably, these funds do not include $14 million USD in grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.
With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to enter the market with blockbuster potential.
Mariusz Olejniczak
CEOwww.eudendron.com
Mauro Angiolini
CEOXuanzhu Biopharmaceutical Co., Ltd.
Jasper Pei
BD managerYangtze River PG 扬子江药业集团江苏紫龙药业有限公司
生产、质量、研发、推广于一体的现代化综合性制药企业。紫龙药业位于江苏省常州市新北区生命健
康产业园区内,紧靠沪宁高速、江宜高速、常州高铁站以及奔牛机场,地理位置得天独厚。总投资达
到16亿元,项目用地面积344亩,现有员工400余人。主要生产剂型包括:固体制剂、小容量注射剂、
冻干粉针剂等。截至目前,紫龙药业生产车间已全部通过新版GMP认证。
波 张
BD经理ZJ Future
With the vision of accelerating enterprise development and growth, we leverage the complementary advantages of North America, Europe, South America, and the Asia-Pacific regions to connect high-quality projects with industry leaders, promote academic communications and interactions in high-tech fields, aggregate global entrepreneurial and innovative resources, build an effective and efficient global innovation ecosystem, and develop high-level and multi-field cooperation in the fields of economy, trade, investment, science, and technology.